AXGN logo

Axogen Inc. (AXGN)

$55.37

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on AXGN

Market cap

$3.31B

EPS

-0.65

P/E ratio

--

Price to sales

8.44

Dividend yield

--

Beta

1.212063

Price on AXGN

Previous close

$55.38

Today's open

$55.15

Day's range

$54.50 - $56.87

52 week range

$23 - $59.72

Profile about AXGN

CEO

Michael Dale

Employees

622

Headquarters

Alachua, FL

Exchange

NASDAQ Capital Market

Shares outstanding

59730715

Issue type

Common Stock

AXGN industries and sectors

Healthcare

Medical Equipment & Supplies

News on AXGN

AxoGen: 3 Key Takeaways for Long-Term Investors

AxoGen raised full-year 2026 revenue guidance to at least $290 million. Commercial payer coverage for Avance reached 96% of covered U.S. lives.

news source

The Motley Fool • Nov 16, 2026

news preview

AxoGen (AXGN) is a Great Momentum Stock: Should You Buy?

Does AxoGen (AXGN) have what it takes to be a top stock pick for momentum investors? Let's find out.

news source

Zacks Investment Research • Nov 12, 2026

news preview

Axogen, Inc. (AXGN) Discusses Prostate Nerve Reconstruction Market Development Transcript

Axogen, Inc. (AXGN) Discusses Prostate Nerve Reconstruction Market Development Transcript

news source

Seeking Alpha • Nov 9, 2026

news preview

Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences

ALACHUA, Fla. and TAMPA, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that management is scheduled to participate in three upcoming investor conferences:

news source

GlobeNewsWire • Nov 3, 2026

news preview

GMED vs. AXGN: Which Stock Should Value Investors Buy Now?

Investors interested in stocks from the Medical - Instruments sector have probably already heard of Globus Medical (GMED) and AxoGen (AXGN). But which of these two companies is the best option for those looking for undervalued stocks?

news source

Zacks Investment Research • Nov 2, 2026

news preview

Axogen: Taking The Friction Out Of Nerve Repair

Axogen (AXGN) is evolving from a growth story to the default procedural platform in peripheral nerve repair, protected by a regulatory moat for the next decade. Q3 2026 saw 26% revenue growth, 45% adjusted EBITDA growth, and operating leverage outpacing dilution, with guidance for at least $290M in 2026 sales and 73%+ gross margin. The $200M BioCircuit (NerveTape) acquisition eliminates technical barriers for surgeons, expands the addressable market, and is accretive at 5.9x expected 2027 sales.

news source

Seeking Alpha • Oct 30, 2026

news preview

Is AxoGen (AXGN) Outperforming Other Medical Stocks This Year?

Here is how AxoGen (AXGN) and BioCryst Pharmaceuticals (BCRX) have performed compared to their sector so far this year.

news source

Zacks Investment Research • Oct 29, 2026

news preview

AxoGen Q3 Earnings Call Highlights

AxoGen NASDAQ: AXGN reported third-quarter revenue growth of 26.2% as demand for its nerve-repair products increased across its breast, extremities, oral and maxillofacial, and head-and-neck markets. The company also raised its full-year revenue outlook following the October acquisition of BioCircuit and said it plans to begin prostate nerve reconstruction market-development activities in 2027.

news source

MarketBeat • Oct 28, 2026

news preview

Axogen, Inc. (AXGN) Q3 2026 Earnings Call Transcript

Axogen, Inc. (AXGN) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Oct 28, 2026

news preview

Axogen, Inc. Reports Third Quarter 2026 Financial Results

Raises Full Year Revenue Guidance to at Least 29% Growth or $290 million Raises Full Year Revenue Guidance to at Least 29% Growth or $290 million

news source

GlobeNewsWire • Oct 28, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Axogen Inc.

Open an M1 investment account to buy and sell Axogen Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in AXGN on M1